BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24107828)

  • 21. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
    Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
    Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.
    Cao R; Zhang Y
    Mol Cell; 2004 Jul; 15(1):57-67. PubMed ID: 15225548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
    Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
    Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression.
    Kuser-Abali G; Alptekin A; Cinar B
    Epigenetics; 2014 Apr; 9(4):634-43. PubMed ID: 24499724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of enhancer of zests homolog 2 in lymphoma.
    Guo SQ; Zhang YZ
    Chin Med J (Engl); 2012 Oct; 125(20):3735-9. PubMed ID: 23075734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ezh2 is required for neural crest-derived cartilage and bone formation.
    Schwarz D; Varum S; Zemke M; Schöler A; Baggiolini A; Draganova K; Koseki H; Schübeler D; Sommer L
    Development; 2014 Feb; 141(4):867-77. PubMed ID: 24496623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PRC2-independent chromatin compaction and transcriptional repression in cancer.
    Vallot C; Hérault A; Boyle S; Bickmore WA; Radvanyi F
    Oncogene; 2015 Feb; 34(6):741-51. PubMed ID: 24469045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
    Ott HM; Graves AP; Pappalardi MB; Huddleston M; Halsey WS; Hughes AM; Groy A; Dul E; Jiang Y; Bai Y; Annan R; Verma SK; Knight SD; Kruger RG; Dhanak D; Schwartz B; Tummino PJ; Creasy CL; McCabe MT
    Mol Cancer Ther; 2014 Dec; 13(12):3062-73. PubMed ID: 25253781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
    Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
    Grindheim JM; Nicetto D; Donahue G; Zaret KS
    Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
    Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
    Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
    Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
    Cancer Cell; 2012 Oct; 22(4):506-523. PubMed ID: 23079660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
    Aldana J; Gardner ML; Freitas MA
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation.
    Rush M; Appanah R; Lee S; Lam LL; Goyal P; Lorincz MC
    Epigenetics; 2009 Aug; 4(6):404-14. PubMed ID: 19717977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.
    Hemming S; Cakouros D; Isenmann S; Cooper L; Menicanin D; Zannettino A; Gronthos S
    Stem Cells; 2014 Mar; 32(3):802-15. PubMed ID: 24123378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
    Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
    Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
    Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
    Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
    Chen S; Chen J; Zhan Q; Zhu Y; Chen H; Deng X; Hou Z; Shen B; Chen Y; Peng C
    Oncotarget; 2014 Nov; 5(21):10421-33. PubMed ID: 25431952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
    Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
    Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.